公开(公告)号：EP0321956A1

公开(公告)日：1989-06-28

申请号：EP88121408.4

申请日：1988-12-21

申请人： ZERIA PHARMACEUTICAL CO., LTD.

发明人： Tanaka, Yoshiaki c/o ZERIA PHARMACEUTICAL CO., LTD ,  Aotsuka, Tomoji c/o ZERIA PHARMACEUTICAL CO., LTD ,  Kobayashi, Naomi c/o ZERIA PHARMACEUTICAL CO., LTD ,  Nakata, Naoki c/o ZERIA PHARMACEUTICAL CO., LTD ,  Ogura, Kuniyoshi c/o ZERIA PHARMACEUTICAL CO., LTD ,  Torizuka, Motoki c/o ZERIA PHARMACEUTICAL CO., LTD ,  Miura, Naoyoshi c/o ZERIA PHARMACEUTICAL CO., LTD ,  Arai, Heihachiro c/o ZERIA PHARMACEUTICAL CO., LTD

IPC分类号： C07D417/06 ,  C07D277/06 ,  A61K31/425

CPC分类号： C07D417/06 ,  C07D277/06

摘要： Novel N-substituted amino acid imide derivatives are disclosed. The compounds are represented by formula (I):
wherein n represents an integer of 0 to 5, and X and Y, which may be the same or different, represent a methylene group or a sulfur atom, provided that not both X and Y are methylene groups at the same time. The compounds are useful as a medicine for treating or preventing cerebral circulation disorder, cerebral metabolism disorder, or memory disturbance.

摘要翻译： 新颖的N-取代氨基酸酰亚胺衍生物是游离缺失盘。 该化合物由式（I）表示： worinÑdarstellt至0整数〜5，并且X和Y可以相同或不同，表示亚甲基或硫原子，条件没有两个X 和Y是在所述的Sametime亚甲基基团。 化合物可用作用于治疗或预防脑循环障碍，脑代谢障碍或记忆障碍的药物是有用的。

公开(公告)号：EP4082577A1

公开(公告)日：2022-11-02

申请号：EP20907787.4

申请日：2020-12-25

申请人： Zeria Pharmaceutical Co., Ltd.

发明人： KOBAYASHI, Kunihiko ,  HORII, Takayuki

IPC分类号： A61K45/06 ,  A61K31/121 ,  A61K31/38 ,  A61K31/407 ,  A61K31/5415 ,  A61K31/542 ,  A61K31/63 ,  A61K35/74 ,  A61K39/04 ,  A61K39/39 ,  A61K39/395 ,  A61K41/00 ,  A61N5/10 ,  A61P11/00 ,  A61P35/00 ,  A61P37/04 ,  A61P43/00 ,  G16H20/00

摘要： The present disclosure provides a composition, a combination product, a medical device and the like for treating or preventing cancer or a tumor or preventing the recurrence of the cancer or the tumor. The present disclosure provides a composition, a combination product and a medical device for treating or preventing cancer or a tumor or preventing the recurrence of the cancer or the tumor, each of which comprises an immune checkpoint inhibitor and a dendritic cell direct activator or means. In another aspect, the present disclosure provides: a novel cancer treatment method which comprises carrying out a treatment of cancer by employing a combination of a treatment by the administration of an immune checkpoint inhibitor and a treatment for improving the sensitivity to the immune checkpoint inhibitor and, therefore, can be used as an immunotherapy that can be expected to have an excellent therapeutic effect; and a medicine which can be used for the cancer treatment method.

公开(公告)号：EP2269975B1

公开(公告)日：2015-07-29

申请号：EP10010897.6

申请日：2005-08-23

申请人： ZERIA PHARMACEUTICAL CO., LTD.

发明人： Nagasawa, Masaaki ,  Asami, Kazuyasu ,  Nakao, Ryu ,  Tanaka, Nobuyuki ,  Aida, Yoshiyuki

IPC分类号： C07C67/08 ,  C07C67/11 ,  C07C69/92 ,  C07D277/20 ,  C07D277/56 ,  C07C51/377 ,  C07C51/347 ,  C07C205/60 ,  C07D277/46

CPC分类号： C07C69/92 ,  C07C51/347 ,  C07C51/377 ,  C07C67/08 ,  C07C205/60 ,  C07D277/46 ,  C07D277/56 ,  C07C65/05

公开(公告)号：EP2269997B1

公开(公告)日：2014-02-26

申请号：EP10010896.8

申请日：2005-08-23

申请人： ZERIA PHARMACEUTICAL CO., LTD.

发明人： Nagasawa, Masaaki ,  Asami, Kazuyasu ,  Nakao, Ryu ,  Tanaka, Nobuyuki ,  Aida, Yoshiyuki

IPC分类号： C07D277/56 ,  C07C51/377

CPC分类号： C07C69/92 ,  C07C51/347 ,  C07C51/377 ,  C07C67/08 ,  C07C205/60 ,  C07D277/46 ,  C07D277/56 ,  C07C65/05

公开(公告)号：EP1493441B1

公开(公告)日：2011-08-31

申请号：EP03745958.3

申请日：2003-04-08

申请人： ZERIA PHARMACEUTICAL CO., LTD.

发明人： MATSUNAGA, Yugo, Zeria Pharmaceutical Co., Ltd. ,  UEKI, Shigeru, Zeria Pharmaceutical Co., Ltd. ,  HIGASHINO, Raita, Zeria Pharmaceutical Co., Ltd. ,  KAWACHI, Masanao, Zeria Pharmaceutical Co., Ltd. ,  KATO, Hiroki, Zeria Pharmaceutical Co., Ltd. ,  KOBAYASHI, Shiro, Zeria Pharmaceutical Co., Ltd.

IPC分类号： A61K31/426 ,  A61P1/00 ,  C07D277/56 ,  A61K31/34 ,  A61K31/38 ,  A61K31/42

CPC分类号： A61K31/426 ,  C07D277/56 ,  C07D307/68

摘要： A therapeutic agent for food competence disorders in the stomach which contains as an active ingredient a compound represented by the general formula (1): (1) (wherein R1 represents hydrogen, hydroxy, or halogeno; A represents furyl, thienyl, thiazolyl, or oxazolyl; R2 and R3 each represents C1-5 alkyl; and n is an integer of 2 to 4) or an acid addition salt of the compound. This medicine functions to relax the gastric fundic part and alleviates food competence disorders in the stomach. It is hence effective in greatly alleviating symptoms caused by such disorders, such as early satiety and epigastric meteorism.

公开(公告)号：EP2305654A1

公开(公告)日：2011-04-06

申请号：EP09746375.6

申请日：2009-05-14

申请人： Zeria Pharmaceutical Co., Ltd.

发明人： YOSHINAGA, Koji ,  HAMANO, Hiroki ,  HORII, Takayuki

IPC分类号： C07D243/12 ,  A61K31/551 ,  A61K45/00 ,  A61P25/04

CPC分类号： C07D243/12 ,  A61K31/551 ,  A61K45/06

摘要： To provide a cancer pain therapeutic and/or prophylactic agent which can be administered to a patient for a long period of time from the early stage to the final stage of the cancer pain therapy, instead of conventional non-opioid analgesic agents or opioid analgesic agents.
The cancer pain therapeutic and/or prophylactic agent containing, as an active ingredient, a 1,5-benzodiazepine derivative represented by formula (1):
(wherein R 1 represents a C 1-6 alkyl group, R 2 represents a phenyl group or a cyclohexyl group, and Y represents a single bond or a C 1-4 an alkylene group) or a pharmaceutically acceptable salt thereof.

摘要翻译： 为了提供可以从癌症疼痛治疗的早期阶段至最终阶段长期施用于患者的癌症疼痛治疗剂和/或预防剂，而不是常规的非阿片样物质止痛剂或阿片类止痛剂 。 含有式（1）所示的1,5-苯并二氮杂衍生物作为活性成分的癌症疼痛治疗和/或预防剂：其中R 1表示C 1-6烷基，R 2表示苯基或 环己基，Y表示单键或C 1-4亚烷基）或其药学上可接受的盐。

公开(公告)号：EP1315488B1

公开(公告)日：2006-10-25

申请号：EP01930024.3

申请日：2001-05-10

申请人： ZERIA PHARMACEUTICAL CO., LTD.

发明人： UEKI, Shigeru, c/o Zeria Pharmaceutical Co., Ltd. ,  HORI, Yuko, c/o Zeria Pharmaceutical Co., Ltd. ,  MATSUNAGA, Yugo, c/o Zeria Pharmeutical Co., Ltd. ,  NAGASAWA, Masaaki, Zeria Pharmaceutical Co., Ltd. ,  NISHIOKA, Hiroyasu, Zeria Pharmaceutical Co., Ltd. ,  MURATA, Masakazu, c/o Zeria Pharmaceutical Co.,Ltd

IPC分类号： A61K31/426 ,  A61P1/00

CPC分类号： A61K31/426 ,  A61K31/381

摘要： Remedies effective for the improvement of colonic motor dysfunction such as irritable bowel syndrome, constipation or intestinal atony without causing side effects on the central nerve system. These colonic motor dysfunction remedies comprise, as active ingredients, aminothiazole derivatives represented by the following formula (I) or a salt or hydrate thereof: wherein R , R and R may be the same or different and each independently represent a hydrogen atom or a hydroxyl, lower alkyl, lower alkoxy, amino, nitro or cyano group, R and R may be the same or different and each independently represent a hydrogen atom or a lower alkyl group, and n stands for an integer of from 2 to 4.

公开(公告)号：EP0945445B9

公开(公告)日：2005-12-28

申请号：EP97947872.4

申请日：1997-12-10

申请人： ZERIA PHARMACEUTICAL CO., LTD.

发明人： SHINOZAKI, Katsuo, Zeria Pharmaceutical Co., Ltd. ,  YONETA, Tomoyuki, Zeria Pharmaceutical Co., Ltd. ,  MURATA Masakazu, Zeria Pharmaceutical Co., Ltd. ,  MIURA, Naoyoshi, Zeria Pharmaceutical Co., Ltd. ,  MAEDA, Kiyoto, Zeria Pharmaceutical Co., Ltd.

IPC分类号： C07D243/12 ,  C07D401/12 ,  C07D403/12 ,  C07D405/12 ,  C07D409/12 ,  C07D401/06 ,  C07D403/06 ,  C07D405/06 ,  C07D409/06 ,  C07D409/14 ,  C07D413/12 ,  A61K31/55

CPC分类号： C07D401/06 ,  C07D243/12 ,  C07D403/06 ,  C07D403/12 ,  C07D405/06 ,  C07D405/12 ,  C07D409/06 ,  C07D409/12 ,  C07D409/14 ,  C07D413/12

公开(公告)号：EP1375534A1

公开(公告)日：2004-01-02

申请号：EP02715864.1

申请日：2002-01-22

申请人： Zeria Pharmaceutical Co., Ltd.

发明人： UOZUMI, Yasuhiro ,  NAKAO, Ryu, ZERIA PHARMACEUTICAL CO. LTD C. R. L.

IPC分类号： C08F8/00 ,  B01J31/22 ,  B01J31/28 ,  C07C51/00 ,  C07C63/06 ,  C07C67/28 ,  C07C69/78 ,  C07C51/23 ,  C07C53/126 ,  C07C49/223 ,  C07C49/78 ,  C07C49/413 ,  C07C47/54 ,  C07C45/38 ,  C07C45/39 ,  C07C45/36 ,  C07C45/68 ,  C07C1/32 ,  C07C15/14

CPC分类号： C08F8/42 ,  B01J23/44 ,  B01J23/72 ,  B01J31/1658 ,  B01J31/1815 ,  B01J2231/4211 ,  B01J2231/44 ,  B01J2231/70 ,  B01J2231/76 ,  B01J2531/16 ,  B01J2531/822 ,  B01J2531/824 ,  B01J2531/828 ,  B01J2531/845 ,  B01J2531/847 ,  C07C1/321 ,  C07C45/36 ,  C07C45/38 ,  C07C45/39 ,  C07C45/45 ,  C07C45/68 ,  C07C49/223 ,  C07C51/145 ,  C07C51/235 ,  C07C67/00 ,  C07C2531/22 ,  C07C2601/16 ,  C07C2601/18 ,  C08F8/30 ,  C07C15/14 ,  C07C49/78 ,  C07C47/54 ,  C07C49/413 ,  C07C63/06 ,  C07C53/126 ,  C07C69/78

摘要： Solid-supported transition metal complex catalysts each of which is represented by the following formula (I) :
wherein A represents a polystyrene-polyethylene glycol copolymer resin, Q represents a heterocycle which may be substituted by one or more lower alkyl groups, lower alkoxy groups or halogen atoms, L 1 and L 2 may be the same or different and each represents a halogen atom or an acetoxy, trifluoroacetoxy, trifluoromethanesulfonyl, tetrafluoroborate or π-allyl group, and M represents copper, palladium, nickel, cobalt, rhodium or platinum; and S-solid-supported transition metal catalysts each of which comprises a compound, which is represented by the following formula (II):
wherein A and Q have the same meanings as defined above, and a transition metal selected from copper, palladium, nickel, cobalt, rhodium or platinum and supported on said compound.
These catalysts are usable for a wide variety of reactions, permit conducting the reactions in water systems, exhibit sufficient catalytic functions even in oxygen atmosphere, and allow recovery and reuse.

摘要翻译： 固体负载的过渡金属配合物催化剂，其每一种由下式（I）表示：其中A代表聚苯乙烯 - 聚乙二醇共聚物树脂，Q代表可以被一个或多个低级烷基取代的杂环，低级烷氧基 或卤素原子，L 1和L 2可以相同或不同，各自代表卤原子或乙酰氧基，三氟乙酰氧基，三氟甲磺酰基，四氟硼酸根或π-烯丙基，M代表铜，钯，镍，钴，铑或铂; 和各自含有由下式（II）表示的化合物的S-固体负载的过渡金属催化剂：其中A和Q具有与上述定义相同的含义，以及选自铜，钯，镍 ，钴，铑或铂并负载在所述化合物上。 这些催化剂可用于各种反应，允许在水体系中进行反应，即使在氧气氛中也显示出足够的催化功能，并且允许回收和再利用。

公开(公告)号：EP0893999B8

公开(公告)日：2003-01-02

申请号：EP97907336.8

申请日：1997-03-17

申请人： NISSAN CHEMICAL INDUSTRIES, LIMITED ,  ZERIA PHARMACEUTICAL CO., LTD.

发明人： MIYAMOTO, Misao, Nissan Chemical Industries, Ltd. ,  ODA, Toshihisa, Nissan Chemical Industries, Ltd. ,  BUNRIN, Toyohiko, Nissan Chemical Industries, Ltd ,  OKABE,Toshio ,  NISHIYAMA, Tetsuyuki, Zeria Pharmaceutical Co.Ltd.

IPC分类号： A61K31/675 ,  A61K9/14

CPC分类号： A61K9/146 ,  A61K9/145 ,  A61K9/1617 ,  A61K9/1652 ,  A61K31/66 ,  A61K31/675

摘要： The present invention can form an amorphous solid dispersion of efonidipine hydrochloride having a high intestinal absorbability which can be formed by subjecting a mixture containing efonidipine hydrochloride of formula (I), hydroxypropylmethylcellulose acetate succinate and optionally a thermostabilizer to a step A of heat treatment at from 85 to 140 DEG C or mechanochemical treatment at from 0 to 140 DEG C, and then to a step B of dipping treatment into a water-containing solution, impregnation treatment with a water-containing solution or contacting treatment with a water vapor-containing gas; or treating the above-mentioned mixture with a hot steam at from 100 to 140 DEG C and a high pressure. Further, in the above-mentioned step A, the mixture is subjected to high frequency heating, making it possible to give a solid dispersion of efonidipine hydrochloride having a high intestinal absorbability without using the step B. This process is quite advantageous in the production in that the use of an organic solvent is not required.